ArticleArchives of Razi Institute2024
Investigation of the Effects of Curcumin on GLP1-R in Liver Tissue of Diabetic Rats.
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study was designed to investigate the effect of curcumin, known for its antidiabetic properties, on the immunohistochemical localization and gene expression of glucagon-like peptide-1 receptor (GLP-1R) in the liver tissues of experimental diabetic rats using reverse transcription polymerase chain reaction (RT-PCR). For this, 24 Sprague-Dawley rats were divided into four groups-control, sham, diabetic, and diabetic + curcumin groups. The control group received no treatment, and 50 mg/kg streptozotocin was administered to the rats in the diabetic and diabetic + curcumin groups received 50 mg/kg streptozotocin. Once diabetes had been established, 100 mg/kg of curcumin was administered intraperitoneally to rats in the diabetic + curcumin group for a period of 21 days. Thesham group was administeredintraperitoneal ethanol and isotonic sodium chloride solution. At the ends of the experiment,tissues were subjected to histological and immunohistochemical examination to ascertain the localization of GLP-1R. Additionally, RT-PCR was employed to determine the levels of GLP-1R gene expression.The histological examinations revealed that the tissue samples from the control and sham groups exhibited a normal histological structure. In contrasr, the diabetic group displayed a range of degenerative changes, including enlargement of the sinusoidal wall enlargement and vacuolization of the hepatocytes. Furthermore, these degenerative findings were mitigated in the diabetic + curcumin group. In the immunohistochemical examinations, the majority of hepatocytes surrounding the vena centralis, as well as some endothelial, and some Kupffer cells,exhibited positively for GLP-1R. The diabetic group exhibited reduced immunoreactivity, while the diabetic + curcumin group demonstrated elevated immunoreactivity compared to the diabetes group. With regard to the molecular analysis, the mean expression level was observed to be higher in the diabetes + curcumin group. However, no significant difference in GLP-1R gene expression was identified between the groups. In conclusion, the administration of curcumin was observed to enhance GLP-1R expression in the liver of the rats with diabetes. Given that GLP-1R is a targets for diabetes treatment, curcumin can be used as a viable therapeutic agent for treating diabetes and alleviating its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.